Theracos BEST – Bexagliflozin Efficacy and Safety Trial


Purpose: to test a drug called Bexagliflozin for patients with Type 2 Diabetes that have an increased risk of cardiovascular disease.

Inclusion Criteria

  • Male or female with an age ≥ 40 years
  • Diagnosis of Type 2 Diabetes
  • HbA1c: 7.5%-11.0%
  • No changes in dose or frequency of Oral Hypoglycemic Agents or GLP-1 agonists
  • Present with one of the following histories: 1) A history of atherosclerotic vascular disease (examples: myocardial infarction, ischemic stroke, revascularization). 2) A history of NHYA class II or III (heart failure). 3) Age ≥ 55 with 2 or more of the following: diabetes > 10 years, uncontrolled high blood pressure, current smoking, uncontrolled high cholesterol

Exclusion Criteria

  • Diagnosis of Type 1 Diabetes
  • Frequent low blood sugar
  • Genitourinary tract infection within 6 weeks
  • History of cancer, active or in remission < 3 years
  • History of alcohol or drug abuse
  • History of MI, stroke or heart failure < 3 months
  • NHYA Class IV
  • Hospitalization for glycemic control (hyperglycemia or hypoglycemia) within the past month
  • Treatment with Bexagliflozin or SGLT2 inhibitors
  • Renal transplant or nephrotic syndrome
  • Pregnant or nursing female


Please contact Katarina Vukojicic, Theracos research coordinator, for more information:


UNC Diabetes Care Center


If you join Theracos, you will receive all medications and supplies at no cost to you.